COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results ...
News Medical on MSN11h
Dual-target drug may lead to new treatment approach for breast cancer patientsResearchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at ...
Tuesday, the agency signed off on SpringWorks’ Gomekli (mirdametinib) as a treatment for the rare genetic disorder ...
Ascendis Pharma (ASND) reported its fourth-quarter 2024 earnings, highlighting a significant revenue increase and a positive market reaction. The company posted total revenue of €173.9 million for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback